This is a StreetInsider.com Premium Only Page

Allergan (AGN) – Press Releases

Apr 24, 2024 07:47 AM Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024

Apr 11, 2024 07:00 AM Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024

Apr 1, 2024 07:00 AM Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset

Mar 27, 2024 12:04 PM Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

Feb 22, 2024 04:16 PM ALAMO GROUP INC. ANNOUNCES RETIREMENT OF BOARD MEMBER, APPOINTMENT OF NEW BOARD CHAIR AND APPOINTMENT OF NEW DIRECTOR

Jan 31, 2024 07:00 AM Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD

Jan 11, 2024 07:00 AM Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis

Dec 27, 2023 04:01 PM Algernon Pharmaceuticals Announces Closing of Private Placement

Dec 27, 2023 07:00 AM Algernon Pharmaceuticals Announces Increase to Private Placement

Dec 20, 2023 02:29 PM AM Best Affirms Credit Ratings of Members of Aegon Ltd.’s U.S. Subsidiaries

Dec 12, 2023 07:42 PM Algernon Pharmaceuticals Announces Private Placement

Nov 30, 2023 07:00 AM Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD

Nov 22, 2023 07:00 AM Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

Nov 9, 2023 02:00 AM Albert Benchimol to be nominated as non-executive member of the Board of Directors

Nov 8, 2023 07:00 AM Algernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with Repirinast

Sep 30, 2023 10:28 AM Redomiciliation to Bermuda completed

Sep 29, 2023 05:44 AM Extraordinary General Meeting approves first step in redomiciliation to Bermuda

Sep 6, 2023 07:00 AM Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH

Aug 8, 2023 07:00 AM Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study

Jul 14, 2023 06:00 PM Algernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory Agreement

Jul 4, 2023 02:06 AM Aegon completes transaction with a.s.r.

Jun 27, 2023 07:00 AM Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program

Jun 6, 2023 07:00 AM Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference

Jun 5, 2023 07:00 AM Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies

May 31, 2023 07:19 AM Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD

May 5, 2023 05:00 PM Algernon Pharmaceuticals Announces Closing of Rights Offering

Apr 27, 2023 07:00 AM Aegon Asset Management and Lakemore Partners Announce Strategic Partnership

Apr 26, 2023 02:00 AM Aegon Bank publishes its 2022 Annual Report

Apr 20, 2023 07:00 AM Algernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching Cut Off Date and Time

Apr 17, 2023 07:00 AM Algernon Pharmaceuticals Announces Notice of Allowance for Method of Use U.S. Patent Application

Apr 13, 2023 02:00 AM Aegon publishes agenda for 2023 Annual General Meeting

Apr 4, 2023 07:00 AM Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical Study

Apr 4, 2023 02:00 AM Aegon UK to divest its individual protection book

Apr 3, 2023 07:00 AM Algernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II Offering to Raise up to USD $10M

Mar 21, 2023 07:00 AM Algernon Pharmaceuticals Announces Launch of Rights Offering

Mar 16, 2023 06:00 AM Aegon publishes its 2022 Integrated Annual Report

Mar 9, 2023 04:30 AM Aegon hosts educational webinar on IFRS 17 and IFRS 9

Mar 2, 2023 08:00 AM Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Board

Feb 28, 2023 08:45 PM Algernon Pharmaceuticals Announces 4 for 1 Forward Share Split

Feb 21, 2023 07:00 AM Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT; Appoints Global TBI Expert as Advisor

Feb 16, 2023 07:00 AM Algernon NeuroScience Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase

Feb 9, 2023 01:00 AM Aegon reports fourth quarter 2022 results

Jan 31, 2023 02:00 AM Aegon completes share buyback program

Jan 17, 2023 10:15 AM Aegon Extraordinary General Meeting approves combination of Aegon’s Dutch businesses with a.s.r.

Jan 17, 2023 07:00 AM Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study

Jan 11, 2023 07:00 AM Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board

Jan 9, 2023 07:00 AM Algernon Pharmaceuticals Announces Plans for a 180 Patient Phase 2b Chronic Cough Study of Ifenprodil

Jan 6, 2023 02:00 AM Aegon to repurchase shares for share-based compensation plans

Jan 3, 2023 07:00 AM Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company’s Psychedelic DMT Stroke Program; Files Form 1-A Offering Statement with U.S. SEC for Regulation A+ Offering

Dec 15, 2022 03:00 PM Aegon completes share buyback programs